iSpecimen Inc. (NASDAQ:ISPC) Short Interest Up 112.1% in May

iSpecimen Inc. (NASDAQ:ISPC) was the recipient of a large increase in short interest during the month of May. As of May 31st, there was short interest totalling 66,600 shares, an increase of 112.1% from the May 15th total of 31,400 shares. Based on an average daily trading volume, of 75,900 shares, the days-to-cover ratio is currently 0.9 days. Currently, 3.1% of the company’s stock are sold short.

iSpecimen Price Performance

Shares of ISPC stock opened at $1.06 on Monday. iSpecimen has a 1-year low of $1.00 and a 1-year high of $11.80. The stock’s fifty day moving average price is $1.21 and its 200 day moving average price is $1.88. The company has a market cap of $2.65 million, a price-to-earnings ratio of -0.06 and a beta of 1.69.

iSpecimen (NASDAQ:ISPC) last announced its earnings results on Monday, May 19th. The company reported ($0.71) earnings per share for the quarter. iSpecimen had a negative return on equity of 139.25% and a negative net margin of 91.66%. The business had revenue of $1.06 million for the quarter.

Institutional Trading of iSpecimen

An institutional investor recently bought a new position in iSpecimen stock. Bridgeway Capital Management LLC purchased a new position in shares of iSpecimen Inc. (NASDAQ:ISPC) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 21,800 shares of the company’s stock, valued at approximately $58,000. Bridgeway Capital Management LLC owned 2.27% of iSpecimen as of its most recent filing with the Securities and Exchange Commission. 13.62% of the stock is owned by hedge funds and other institutional investors.

iSpecimen Company Profile

iSpecimen Inc provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers.